 |
市場調查報告書
商品編碼
1465574
眼科眼藥水市場規模-按滴眼器類型（單劑量、防腐多劑量、不含防腐劑多劑量）、模式（處方、非處方藥）、適應症（青光眼、過敏、乾眼）、最終用途（醫院、眼科）臨床）及預測，2024 - 2032Ophthalmic Eye Dropper Market Size - By Eye Dropper Type (Unidose, Preserved Multi-dose, Preservative-free multi-dose), Mode (Prescription, OTC), Indication (Glaucoma, Allergies, Dry Eye), End-use (Hospital, Ophthalmic Clinic) & Forecast, 2024 - 2032 |
||||||
在眼部護理技術進步和創新眼科藥物開發的推動下，2024年至2032年全球眼科眼藥水市場複合年成長率將達到6.3%。這些進步使得能夠對各種眼部疾病進行更有效和更專業的治療，從而產生了對滴眼器等專業輸送方法的需求。隨著具有特定配方和低黏度的新藥物的出現，精確、高效給藥的需求變得至關重要。這一趨勢提高了患者的便利性並推動了市場規模，反映出眼部護理解決方案的持續發展。
例如，2022 年 10 月，Gerresheimer 推出了一種名為 DropControl 的新型滴管插件，專為當代低黏度眼科藥物而設計，可提供精確、高效的給藥。
眼科滴管產業根據最終用途、滴管類型、適應症、模式和地區進行細分。
由於全球青光眼盛行率不斷上升，青光眼細分市場將在 2032 年顯著成長，從而推動對有效治療方案的需求。隨著眼部護理技術的進步，專為青光眼治療而設計的專用眼藥水可提供精確的劑量控制且易於使用。此外，易患青光眼的老年人口不斷增加，進一步推動了這群人的擴張。隨著人們對定期眼科檢查重要性的認知不斷增強，青光眼領域將站在眼科眼藥水市場的前沿。
在全球專業眼科護理設施激增的推動下，到 2032 年，眼科診所領域的眼科眼藥水市場將顯著成長。這些診所提供從診斷到治療的全面服務，吸引尋求專家護理的患者。憑藉多種眼部護理解決方案，患者可以從針對各種情況的客製化治療中受益。眼科診所的便利性和可近性，加上對專業諮詢不斷成長的需求，極大地促進了該領域在市場上的主導地位。
由於該地區人口不斷成長，加上眼部疾病盛行率不斷上升，亞太地區眼科滴管產業從 2024 年到 2032 年將呈現顯著的複合年成長率。中國和印度等國家由於人口眾多且眼保健設施的普及程度不斷提高，因此在這項擴張的主要貢獻者中發揮關鍵作用。此外，醫療保健基礎設施的崛起和技術進步將進一步鞏固亞太地區作為眼科眼藥水市場主要貢獻者的地位。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 眼部疾病盛行率增加
- 眼科藥物傳輸系統的技術進步
- 老年人口增加與疾病相伴
- 提高認知和診斷
- 產業陷阱與挑戰
- 不合規和依從性差
- 相關副作用和耐受性問題
- 成長動力
- 成長潛力分析
- 監管環境
- 技術景觀
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 競爭定位矩陣
- 戰略展望矩陣
第 5 章：市場估計與預測：按滴管法，2018 - 2032 年
- 主要趨勢
- 單劑量眼藥水
- 保存多劑量滴眼器
- 不含防腐劑的多劑量眼藥水
第 6 章：市場估計與預測：按模式，2018 - 2032
- 主要趨勢
- 處方藥
- 非處方 (OTC) 藥物
第 7 章：市場估計與預測：按指標分類，2018 年 - 2032 年
- 主要趨勢
- 青光眼
- 過敏
- 結膜炎
- 乾眼症
- 其他適應症
第 8 章：市場估計與預測：按最終用途，2018 - 2032 年
- 主要趨勢
- 醫院
- 眼科診所
- 家庭護理設置
- 其他最終用戶
第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 歐洲其他地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 10 章：公司簡介
- AbbVie Inc.
- Alcon plc
- AptarGroup, Inc.
- Bausch & Lomb Incorporated
- Novartis AG
- PanOptica, Inc.
- Pfizer Inc
- Sager Pharma Kft
- Silgan Dispensing Systems LLC
- Similasan Corp
Global Ophthalmic Eye Dropper Market will record a 6.3% CAGR between 2024 and 2032, propelled by advancements in eye care technology and the development of innovative ophthalmic medications. These advancements enable more effective and specialized treatments for various eye conditions, creating a demand for specialized delivery methods like eye droppers. As new medications with specific formulations and low viscosities emerge, the need for precise and efficient administration becomes crucial. This trend enhances patient convenience and drives market size, reflecting the continuous evolution of eye care solutions.
For instance, in October 2022, Gerresheimer introduced a novel dropper insert called DropControl, specifically designed for contemporary ophthalmic medications with low viscosity, providing precise and efficient administration.
The ophthalmic eye dropper industry is fragmented based on end-use, eye dropper type, indication, mode, and region.
The glaucoma segment will see a notable surge by 2032, attributed to the rising prevalence of glaucoma worldwide, driving demand for effective treatment options. With advancements in eye care technology, specialized eye droppers tailored for glaucoma management offer precise dosage control and ease of use. Additionally, the increasing elderly population, susceptible to glaucoma, further propels this segment's expansion. As awareness grows regarding the importance of regular eye examinations, the glaucoma segment will stand at the forefront of the ophthalmic eye dropper market.
The ophthalmic eye dropper market from the ophthalmic clinic segment will amass remarkable gains through 2032, fueled by the proliferation of specialized eye care facilities globally. These clinics offer a comprehensive range of services, from diagnosis to treatment, attracting patients seeking expert care. With a diverse array of eye care solutions available, patients benefit from tailored treatments for various conditions. The convenience and accessibility of ophthalmic clinics, coupled with the growing demand for professional consultation, contribute significantly to the segment's dominance in the market.
Asia Pacific ophthalmic eye dropper industry will exhibit a noteworthy CAGR from 2024 to 2032 due to the region's growing population, in line with an increasing prevalence of eye conditions. Countries such as China and India play pivotal roles as major contributors to this expansion, owing to their vast populations and improving access to eye care facilities. Additionally, the rise of healthcare infrastructure and technological improvements will further solidify Asia Pacific's position as the leading contributor to the ophthalmic eye dropper market.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Base estimates & calculations
- 1.3 Data collection
- 1.4 Forecast parameters
- 1.5 Data validation
- 1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
- 1.6.2.1 Paid sources
- 1.6.2.2 Public sources
Chapter 2 Executive Summary
- 2.1 Industry 360-degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of eye disorders
- 3.2.1.2 Technological advancements in ophthalmic drug delivery systems
- 3.2.1.3 Increasing geriatric population coupled with disease
- 3.2.1.4 Increasing awareness and diagnosis
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Non-compliance and poor adherence
- 3.2.2.2 Associated side effects and tolerance issues
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.6 Porter's analysis
- 3.6.1 Supplier power
- 3.6.2 Buyer power
- 3.6.3 Threat of new entrants
- 3.6.4 Threat of substitutes
- 3.6.5 Industry rivalry
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Competitive positioning matrix
- 4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Eye Dropper, 2018 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Unidose eye dropper
- 5.3 Preserved multi-dose eye dropper
- 5.4 Preservative-free multi-dose eye dropper
Chapter 6 Market Estimates and Forecast, By Mode, 2018 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Prescription drugs
- 6.3 Over the counter (OTC) drugs
Chapter 7 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Glaucoma
- 7.3 Allergies
- 7.4 Conjunctivitis
- 7.5 Dry eye
- 7.6 Other indications
Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospitals
- 8.3 Ophthalmic clinics
- 8.4 Homecare settings
- 8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Spain
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 AbbVie Inc.
- 10.2 Alcon plc
- 10.3 AptarGroup, Inc.
- 10.4 Bausch & Lomb Incorporated
- 10.5 Novartis AG
- 10.6 PanOptica, Inc.
- 10.7 Pfizer Inc
- 10.8 Sager Pharma Kft
- 10.9 Silgan Dispensing Systems LLC
- 10.10 Similasan Corp
